Literature DB >> 19070878

Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.

Tong-Ming Fu1, Daniel C Freed, Melanie S Horton, Jiang Fan, Michael P Citron, Joseph G Joyce, Victor M Garsky, Danilo R Casimiro, Qinjian Zhao, John W Shiver, Xiaoping Liang.   

Abstract

M2 protein of influenza A virus has been implicated as a target for vaccines with broad cross-strain coverage. Studies in small animal models have shown that antibody responses induced by 23-mer M2 peptide vaccines can provide protection against influenza A virus challenge. To study antiviral mechanisms of Merck M2-OMPC conjugate vaccine, we generated and characterized four M2 peptide-specific monoclonal antibodies (mAbs). Here we demonstrated that the protection by our M2 mAbs is independent of NK-mediated effector functions in mice. The protective mAbs preferentially bind to M2 multimers composed of two or more M2 peptides in parallel orientation. Our findings indicate that the protective M2 Ab prefer to bind to epitopes located within the N-terminal 10 amino acids of the M2 peptide, and the epitopes are likely formed by two M2 peptides in parallel orientation. The implications of these results in antiviral mechanisms of immune responses induced by M2 vaccines are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070878     DOI: 10.1016/j.virol.2008.11.035

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

2.  Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody.

Authors:  Ki Joon Cho; Bert Schepens; Kristof Moonens; Lei Deng; Walter Fiers; Han Remaut; Xavier Saelens
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

3.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.

Authors:  Jae-Min Song; Nico Van Rooijen; Jadranka Bozja; Richard W Compans; Sang-Moo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs.

Authors:  Ning Yang; James S Gibbs; Heather D Hickman; Glennys V Reynoso; Arun K Ghosh; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2016-03-25       Impact factor: 5.422

5.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

6.  Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody.

Authors:  Ki Joon Cho; Bert Schepens; Jong Hyeon Seok; Sella Kim; Kenny Roose; Ji-Hye Lee; Rodrigo Gallardo; Evelien Van Hamme; Joost Schymkowitz; Frederic Rousseau; Walter Fiers; Xavier Saelens; Kyung Hyun Kim
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

7.  Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.

Authors:  Roger R Beerli; Monika Bauer; Nicole Schmitz; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Wolfgang A Renner; Philippe Saudan; Martin F Bachmann
Journal:  Virol J       Date:  2009-12-21       Impact factor: 4.099

8.  Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.

Authors:  Min-Chul Kim; Jong-Seok Lee; Young-Man Kwon; Eunju O; Youn-Jeong Lee; Jun-Gu Choi; Bao-Zhong Wang; Richard W Compans; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2013-06-27       Impact factor: 5.970

9.  A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody.

Authors:  Rashid Manzoor; Nao Eguchi; Reiko Yoshida; Hiroichi Ozaki; Tatsunari Kondoh; Kosuke Okuya; Hiroko Miyamoto; Ayato Takada
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

10.  Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.

Authors:  Li Wang; Annie Hess; Timothy Z Chang; Ying-Chun Wang; Julie A Champion; Richard W Compans; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2013-08-27       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.